Please use this identifier to cite or link to this item:
https://doi.org/10.15252/emmm.202012697
Title: | Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients | Authors: | Stebbing, J. Krishnan, V. de Bono, S. Ottaviani, S. Casalini, G. Richardson, P.J. Monteil, V. Lauschke, V.M. Mirazimi, A. Youhanna, S. Tan, Y.-J. Baldanti, F. Sarasini, A. Terres, J.A.R. Nickoloff, B.J. Higgs, R.E. Rocha, G. Byers, N.L. Schlichting, D.E. Nirula, A. Cardoso, A. Corbellino, M. |
Keywords: | anti-cytokine anti-viral baricitinib case series COVID-19 |
Issue Date: | 2020 | Publisher: | Blackwell Publishing Ltd | Citation: | Stebbing, J., Krishnan, V., de Bono, S., Ottaviani, S., Casalini, G., Richardson, P.J., Monteil, V., Lauschke, V.M., Mirazimi, A., Youhanna, S., Tan, Y.-J., Baldanti, F., Sarasini, A., Terres, J.A.R., Nickoloff, B.J., Higgs, R.E., Rocha, G., Byers, N.L., Schlichting, D.E., Nirula, A., Cardoso, A., Corbellino, M. (2020). Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Molecular Medicine 12 (8) : e12697. ScholarBank@NUS Repository. https://doi.org/10.15252/emmm.202012697 | Rights: | Attribution 4.0 International | Abstract: | Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID-19 infection via proposed anti-cytokine effects and as an inhibitor of host cell viral propagation. We evaluated the in vitro pharmacology of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection. We validated the AI-predicted biochemical inhibitory effects of baricitinib on human numb-associated kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK. Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids. These effects occurred at exposure levels seen clinically. In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was associated with clinical and radiologic recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels. Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and support its assessment in randomized trials in hospitalized COVID-19 patients. © 2020 Eli Lilly and Company Published under the terms of the CC BY 4.0 license | Source Title: | EMBO Molecular Medicine | URI: | https://scholarbank.nus.edu.sg/handle/10635/197913 | ISSN: | 1757-4676 | DOI: | 10.15252/emmm.202012697 | Rights: | Attribution 4.0 International |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_15252_emmm_202012697.pdf | 1.28 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License